Menu

Prexige

The world decides the fate of the Cox-2s

0

I hate to bring up the topic of Cox-2 inhibitors one more time, but I did want to let you know in brief what has been happening.  In various places in the world, the judgment has been much the same.  For example, Europe and the USA seem to be both deciding to allow Cox-2 inhibitors for now (these include brands like Dynastat, Prexige, Bextra, Celebrex and Arcoxia), but with restrictions on their use and labeling.  Many other countries, such as India and Australia have done the same thing.  In the USA’s FDA proceedings, both Bextra and Celebrex "passed", although the vote was extremely close in the case of Bextra.

And for the surprise twist, Vioxx itself may be reintroduced to the market.  It’s not that the risks on these drugs have suddenly vanished.  The question is, do the benefits to some patients outweigh the risks.  So be reminded again – educate yourself, talk to your doctor, keep track of your medical history and tell her about it, get a second opinion if you feel you need one, and don’t take drugs you don’t have to.  What you "have to" take is where the difference of opinion lies – but it’s your responsibility to make an informed decision.

FDA Health Advisory – Bextra, Celebrex and Aleve

, 0

Yesterday the American FDA issued a health advisory regarding the drugs Cox-2 drugs Bextra and Celebrex, and the NSAID naproxen.  Basically, they’re recommending that caution should be exercised with the drugs Bextra and Celebrex.  Recent studies seem to indicate that they may increase the risk of heart attack and stroke.  There is also concern about naproxen (popularly sold as Aleve, Anaprox,Naprosyn and others), which is not a Cox-2 drug like Bextra.  Recent studies show that naproxen may also increase risk of heart problems.  If you’re taking naproxen in any form for more than 10 days, talk to your doctor.  If you’re on any of these drugs and you have any history of heart trouble, talk to your doctor.  The FDA is awaiting further reviews on these drugs.  You can read yesterday’s health advisory put out by the FDA on their website.  WebMD has some excellent information on some of the recent studies involving Bextra.

Cox-2 Inhibitors – in the news again

, 0

The information is coming in so fast that it’s hard to keep up to date! Many of you read in the last issue of HeadWay about emerging concerns about drugs such as Celebrex and Bextra. Now these drugs are getting more attention, and more studies are being done. You will notice some updates in this article about Cox2 Inhibitors, which will hopefully clear up some of your questions. Although the Vice-President of the US National Cancer Institute urges caution about jumping to conclusions about this study, I think we should continue to be cautious about using these drugs until more studies are completed.

Back To Top
The articles on Headache and Migraine News are © 2004-2026 J. Cottrill.
Every effort is made to ensure the accuracy of each article, and to point you to further sources of information. However, this site is for informational purposes only and should never replace a visit to your doctor.